Editor’s Perspective: Is The Ketek Scandal Good For Big Pharma? Generic Biologic Bill Could Suffer

It was not a pretty sight in Room 2123 of the Rayburn House Office Building on Feb. 12, where the House's Energy and Commerce Committee's Oversight and Investigations Subcommittee held a hearing on fraud in the studies of the antibiotic Ketek. The head of Sanofi-Aventis' U.S. R&D had to acknowledge he could not verify that other studies were free from fraud, and committee members lambasted FDA Commissioner Andrew von Eschenbach in absentia

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet